Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. - Wikidata - wikimedia - TriplyDB

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.

http://www.wikidata.org/entity/Q43904258

about

Interleukin-11 for induction of remission in Crohn's disease Trichuris suis therapy in Crohn's disease The structure of human interleukin-11 reveals receptor-binding site features and structural differences from interleukin-6 Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)?The impact of JNK inhibitor D-JNKI-1 in a murine model of chronic colitis induced by dextran sulfate sodium.Review article: medical treatment of moderate to severe Crohn's disease.Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition.Evaluation of new therapies for inflammatory bowel disease.IL-11 Attenuates Liver Ischemia/Reperfusion Injury (IRI) through STAT3 Signaling Pathway in Mice.STAT3-Activating Cytokines: A Therapeutic Opportunity for Inflammatory Bowel Disease?Novel biological strategies in inflammatory bowel diseases.Biologics in inflammatory bowel disease: how much progress have we made?Biological response modifiers for the treatment of Crohn's disease.Management of ulcerative colitis and Crohn's disease.Safety of biologic therapy.Biologics in Crohn's disease: searching indicators for outcome.Recent advances in the medical therapy of Crohn's disease in childhood.Biologic targeting in the treatment of inflammatory bowel diseases.Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.Investigational agents for Crohn's disease.Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.Cytokine blockade in inflammatory bowel diseases.Translational research and efficacy of biologics in Crohn's disease: a cautionary tale.IL-11 signaling as a therapeutic target for cancer.Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease.Non-core region modulates interleukin-11 signaling activity: generation of agonist and antagonist variants.Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease.Decreased MAPK- and PGE2-dependent IL-11 production in Gialpha2-/- colonic myofibroblasts.The cardioprotective effect of interleukin-11 against ischemia-reperfusion injury in a heart donor model.New insights into the biological therapy of Crohn’s disease

P2860

Q24200762-EBA38996-52FB-4E42-BC5F-13FE50F61C98 Q24685735-DD23F776-4B87-4F0C-AED1-CCC56510137A Q27695574-59B7127F-028C-49D9-9870-5CFFF539E18F Q28236807-0ED6629B-BE6C-4FA3-8736-81B2A2C2192A Q28251305-529626C2-A375-4662-A2E3-58851A3198E9 Q30454726-1A0A9B7D-BB6F-40ED-A965-5D6598BD850A Q35145017-F5EA6C6D-2AC1-4533-A863-023BE921D424 Q35161097-A903A165-46DC-4066-AF8A-6D1E3FE96CE1 Q35216827-D70119B7-063A-4B02-BE53-013424739D6E Q35577573-B6893356-B1E5-4733-A848-905609F880F7 Q35589806-2DCB8940-5888-41CF-B2C5-EB9110706A5C Q35787653-2FBDF457-1AA4-4AEA-818F-300F5C045096 Q35861158-AFD2EFFC-3B0D-477C-B3C9-D3B25D489DB7 Q35925597-B7C30791-1046-49F1-A520-38F49D5E448E Q36004867-F1D71E4C-78D8-440A-A974-2F65FC3EE621 Q36737339-8476FEDD-09E3-442C-A313-C7062BD81783 Q36909385-5DE44E35-10A9-4CED-B9C8-0BE925732EE0 Q36968175-31A2892D-DA82-4679-AEFA-F608FEA4C877 Q37303206-EBE02C1D-5D65-4066-A57D-992AA6A86471 Q37680981-94FFC16F-596B-41DD-9517-5470EB936411 Q37788217-4A25D1DD-ECCD-43B7-ACF2-49A07C3CF6A8 Q37847059-51E0BD11-ACF1-4B44-B751-13ACA5B2B8ED Q37952792-060F8930-5787-4381-BBF4-01F20DFEE069 Q38177338-2BCC3352-F74D-42A5-A57C-16F724E6BAF7 Q38445355-B0A39C19-AEB2-40F9-B4AD-F9F5D7A74AB9 Q39121473-0D04AAF8-5B69-474C-B3A1-A68DC94BF56E Q39622839-EB1F6BAB-72F2-4676-B14B-0CA13D14F079 Q40480568-9FECE5D3-0DDE-4791-BF5A-101392D003BD Q42509061-2356D105-8900-43C9-84C2-B16BEA1526D2 Q55003785-03363876-8EA6-431A-AC01-8E25E363FE0D Q57821547-840DCA28-E8AF-4119-8BF5-8979C2F275C9

P2860

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.

http://www.wikidata.org/entity/Q43904258

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Randomized, controlled trial o ...... s with active Crohn's disease.

@en

Randomized, controlled trial o ...... s with active Crohn's disease.

@nl

type

label

Randomized, controlled trial o ...... s with active Crohn's disease.

@en

Randomized, controlled trial o ...... s with active Crohn's disease.

@nl

prefLabel

Randomized, controlled trial o ...... s with active Crohn's disease.

@en

Randomized, controlled trial o ...... s with active Crohn's disease.

@nl

P1433

Q43904258-2A650410-1D38-4678-8D9D-E3599DFFB141

P1476

Q43904258-57549161-22C3-4F57-8237-73CBD2266CCD

P2093

Q43904258-185AF16A-69FE-49C1-A2DD-32D90E10DA0F

Q43904258-377005AD-FB5A-4E90-9C6F-2934A4152EDE

Q43904258-7B7557B3-E23E-43A8-A889-ECF3681555BB

Q43904258-98C453DC-D571-4261-BE44-83CA04A8C8F4

Q43904258-9B171D4A-D303-4D23-8796-6A7ED9FC761D

Q43904258-B92888E6-6A54-4E2B-959B-EE47546ED372

Q43904258-BDA00C8F-42EF-4641-956D-2AD454FB200B

Q43904258-D99005DC-C4BF-489C-A6B2-B5B4C1BDC0B2

Q43904258-EA4CD680-A13A-4D9A-82DC-793B81721A4B

Q43904258-F34F476F-4C9F-4AF1-BD25-AC7BDEBC3B02

P2860

Q43904258-0EE1ACCE-8C95-4FF6-B6F3-370430A722AB

Q43904258-161D311F-9A17-4105-86DF-C4B27C104C49

Q43904258-5467F59C-0490-437D-8F5F-5ECA7474B933

Q43904258-6BDDF22E-4EA8-4D6F-92A8-5362F0ADFA45

Q43904258-7953E24C-5055-4DB9-8497-1E6B04E479EC

Q43904258-7F5E3B44-0340-425C-A515-39F40502AF19

Q43904258-A605256C-C956-46BD-B5EA-EB1E81F2FED2

Q43904258-A9ED9E14-4BBC-4458-9B30-C0849388EBF8

Q43904258-E588F5DB-455F-46C6-8C8A-A862A58C5425

P304

Q43904258-15567093-80EE-4E37-A2CF-CF4B64769261

P31

Q43904258-1E2228B3-19C9-4C01-95A3-20C6179363B1

P356

Q43904258-6D417811-A0F0-4B36-944D-C019FC216E9C

P407

Q43904258-45B02DB6-77FB-46B0-9BB9-CD1AF6EB48B7

P433

Q43904258-CE4760B7-5F1F-49DE-9225-37C2B4FC4E44

P478

Q43904258-F342FBA5-7088-499E-9C54-C4657D10F888

P577

Q43904258-68B208A8-C830-468E-86C4-34A23D631E06

P5875

Q43904258-AC96A0DB-DD43-4EF1-B741-94B58951F15E

P698

Q43904258-F7B0C96D-741F-4F33-97EE-51B286D911C1

P356

J.1365-2036.2002.01179.X

P1433

Alimentary Pharmacology & Therapeutics

P1476

Randomized, controlled trial o ...... s with active Crohn's disease.

@en

P2093

B D Winston

http://www.w3.org/2001/XMLSchema#string

B E Sands

http://www.w3.org/2001/XMLSchema#string

B Salzberg

http://www.w3.org/2001/XMLSchema#string

C Barish

http://www.w3.org/2001/XMLSchema#string

L Wruble

http://www.w3.org/2001/XMLSchema#string

M Safdi

http://www.w3.org/2001/XMLSchema#string

M Shapiro

http://www.w3.org/2001/XMLSchema#string

R Wilkins

http://www.w3.org/2001/XMLSchema#string

RHIL-11 Crohn's Study group

http://www.w3.org/2001/XMLSchema#string

U S Schwertschlag

http://www.w3.org/2001/XMLSchema#string

P2860

Importance of intestinal mucosal immunity and luminal bacterial cell wall polymers in the aetiology of inflammatory joint diseases.

Treatment of inflammatory bowel disease from now to the millennium.

gp130 transducing receptor cross-linking is sufficient to induce interleukin-6 type responses.

Intestinal permeability of 51Cr-labelled ethylenediaminetetraacetic acid in patients with Crohn's disease and their healthy relatives.

Pharmacokinetics of recombinant human interleukin-11 (rhIL-11) in healthy male subjects

Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats.

Inflammatory bowel disease: etiology and pathogenesis.

Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells.

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

P304

399-406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2036.2002.01179.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11485426

http://www.w3.org/2001/XMLSchema#string

P698

11876692

http://www.w3.org/2001/XMLSchema#string